PE20050077A1 - Derivados de 4-pirrolidino-fenil-bencil-eter - Google Patents

Derivados de 4-pirrolidino-fenil-bencil-eter

Info

Publication number
PE20050077A1
PE20050077A1 PE2003000952A PE2003000952A PE20050077A1 PE 20050077 A1 PE20050077 A1 PE 20050077A1 PE 2003000952 A PE2003000952 A PE 2003000952A PE 2003000952 A PE2003000952 A PE 2003000952A PE 20050077 A1 PE20050077 A1 PE 20050077A1
Authority
PE
Peru
Prior art keywords
phenyl
halogen
pyrrolidine
benzyloxy
oxo
Prior art date
Application number
PE2003000952A
Other languages
English (en)
Inventor
Wolfgang Wostl
Rene Wyler
Synese Jolidon
Andrew William Thomas
Rosa Maria Rodriguez-Sarmiento
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20050077A1 publication Critical patent/PE20050077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X-Y ES -CH2-CH2-, -CH=CH-, -CH2-O-; R1, R1.1 Y R1.2 SON CADA UNO H, HALOGENO, CIANO, ENTRE OTROS; R21, R22 Y R23 SON CADA UNO H, HALOGENO; R24 ES H, HALOGENO, METILO; R3 ES H; R4 ES -CONHR5, -CN O -NHR6; R5 ES H, ALQUILO C1-C3; R6 ES -CO-H, -CO-NH2, -CO-HALOGENO-(C1-C3), ENTRE OTROS. TAMBIEN REFERIDA A PROCESOS PARA SU PREPARACION DONDE SON COMPUESTOS PREFERIDOS: (RS)-1-(4-BENCILOXI-FENIL)-2-OXO-PIRROLIDINA-3-CARBONITRILO; METILAMIDA DEL ACIDO (RS)-1-[4-(3-FLUORO-BENCILOXI)-FENIL]- 2-OXO-PIRROLODINA-3-CARBOXILICO Y (S)-{1-[4-(3-FLUORO-BENCILOXI)-FENIL]-2-OXO-PIRROLIDIN-3-IL}-UREA; ENTRE OTROS; Y SU USO EN LA PREPARACION Y TRATAMIENTO DE ENFERMEDADES MEDIADAS POR INHIBIDORES DE MONOAMINO OXIDASA B COMO LA DE ALZHEIMER O DEMENCIA SENIL, ENTRE OTRAS
PE2003000952A 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil-eter PE20050077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20

Publications (1)

Publication Number Publication Date
PE20050077A1 true PE20050077A1 (es) 2005-03-01

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2003000952A PE20050077A1 (es) 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil-eter
PE2003000956A PE20050078A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
PE2003000958A PE20050079A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2003000956A PE20050078A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
PE2003000958A PE20050079A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Country Status (32)

Country Link
US (4) US7037935B2 (es)
EP (3) EP1542971A1 (es)
JP (3) JP4335142B2 (es)
KR (3) KR100681586B1 (es)
CN (3) CN100400509C (es)
AR (3) AR041297A1 (es)
AT (2) ATE459601T1 (es)
AU (3) AU2003267381B2 (es)
BR (4) BR0314299A (es)
CA (3) CA2496756C (es)
CY (1) CY1110745T1 (es)
DE (2) DE60333202D1 (es)
DK (1) DK1542970T3 (es)
ES (2) ES2338646T3 (es)
GT (3) GT200300206A (es)
HK (3) HK1084383A1 (es)
HR (3) HRP20050262A2 (es)
JO (2) JO2604B1 (es)
MX (3) MXPA05002881A (es)
MY (3) MY134480A (es)
NO (3) NO329754B1 (es)
NZ (3) NZ538046A (es)
PA (3) PA8583001A1 (es)
PE (3) PE20050077A1 (es)
PL (3) PL376018A1 (es)
PT (1) PT1542970E (es)
RU (3) RU2336267C2 (es)
SI (1) SI1542970T1 (es)
TW (3) TWI286132B (es)
UY (3) UY27991A1 (es)
WO (3) WO2004026826A1 (es)
ZA (3) ZA200501137B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
RU2378270C2 (ru) * 2004-08-02 2010-01-10 Ф. Хоффманн-Ля Рош Аг Бензилокси-производные в качестве ингибиторов моноаминоксидазы b
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
AU2006218193A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
DE602006003879D1 (de) * 2005-03-15 2009-01-08 Hoffmann La Roche Verfahren zur herstellung von enantiomerenreinen 4-pyrrolidinophenyl- benzyletherderivaten
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
CA2706017A1 (en) * 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
EP2970125B1 (en) 2013-03-14 2018-07-18 Dart Neuroscience (Cayman) Ltd. Substituted naphthyridine and quinoline compounds as mao inhibitors
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
MX361764B (es) * 2013-10-29 2018-12-17 Hoffmann La Roche Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
WO2016156124A1 (en) 2015-03-27 2016-10-06 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising sembragiline
US11365194B2 (en) 2017-09-27 2022-06-21 Kagoshima University Analgesic drug using PAC1 receptor antagonistic drug
KR20200061381A (ko) 2017-10-05 2020-06-02 바이오젠 인크. 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
WO2019170115A1 (en) 2018-03-08 2019-09-12 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
EP3932490A4 (en) 2019-02-27 2022-11-16 Kagoshima University ANTIPRURIC AGENT USING PAC1 RECEPTOR ANTAGONISTS
WO2021225161A1 (ja) 2020-05-08 2021-11-11 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) * 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
EP0393607B1 (en) 1989-04-19 1996-02-21 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives having a hetero ring
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
EP0906090A1 (en) 1996-03-15 1999-04-07 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
AU4181000A (en) * 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
WO2001058388A1 (en) * 2000-02-10 2001-08-16 Potencia Medical Ag Urinary incontinence treatment with wireless energy supply
EP1255513B1 (en) * 2000-02-14 2005-05-25 Potencia Medical AG Penile prosthesis
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
GT200300205A (es) 2004-04-29
TW200413350A (en) 2004-08-01
JP4335141B2 (ja) 2009-09-30
KR20050057456A (ko) 2005-06-16
EP1542969A1 (en) 2005-06-22
CN1681777A (zh) 2005-10-12
NO20050701L (no) 2005-03-02
HK1084383A1 (en) 2006-07-28
WO2004026826A1 (en) 2004-04-01
RU2336268C2 (ru) 2008-10-20
HK1083498A1 (en) 2006-07-07
JP2006503834A (ja) 2006-02-02
KR100676015B1 (ko) 2007-01-30
JP4335140B2 (ja) 2009-09-30
AR041299A1 (es) 2005-05-11
RU2005111974A (ru) 2006-01-20
US7037935B2 (en) 2006-05-02
US7122562B2 (en) 2006-10-17
SI1542970T1 (sl) 2010-08-31
WO2004026825A1 (en) 2004-04-01
HK1083499A1 (en) 2006-07-07
CA2498335A1 (en) 2004-04-01
UY27990A1 (es) 2004-03-31
DK1542970T3 (da) 2010-08-02
JP2006503833A (ja) 2006-02-02
CN100400509C (zh) 2008-07-09
EP1542971A1 (en) 2005-06-22
US20060122235A1 (en) 2006-06-08
CN1681779A (zh) 2005-10-12
TWI337604B (en) 2011-02-21
NZ538049A (en) 2007-05-31
WO2004026827A1 (en) 2004-04-01
PL376019A1 (en) 2005-12-12
PA8583501A1 (es) 2004-04-23
JO2605B1 (en) 2011-11-01
CA2498785C (en) 2011-07-26
CN1681778A (zh) 2005-10-12
PA8583601A1 (es) 2004-09-16
EP1542970B1 (en) 2010-06-30
MY133332A (en) 2007-11-30
KR100681586B1 (ko) 2007-02-09
AU2003270213B2 (en) 2009-02-12
RU2005111969A (ru) 2006-01-20
CN100383118C (zh) 2008-04-23
KR100676014B1 (ko) 2007-01-30
BR0314299A (pt) 2005-12-13
RU2336267C2 (ru) 2008-10-20
NO20050665L (no) 2005-04-18
ATE472530T1 (de) 2010-07-15
AU2003267381B2 (en) 2009-08-27
BRPI0314631B1 (pt) 2018-04-17
TWI331994B (en) 2010-10-21
JP2006510596A (ja) 2006-03-30
MXPA05002878A (es) 2005-05-27
ES2338646T3 (es) 2010-05-11
HRP20050263B1 (hr) 2013-09-30
AU2003273901A1 (en) 2004-04-08
MY135696A (en) 2008-06-30
CA2496756A1 (en) 2004-04-01
AR041297A1 (es) 2005-05-11
BR0314314A (pt) 2005-07-26
MXPA05002880A (es) 2005-05-27
NO329754B1 (no) 2010-12-13
BR0314631A (pt) 2005-08-02
NO330012B1 (no) 2011-02-07
US20040106650A1 (en) 2004-06-03
CN100503562C (zh) 2009-06-24
US7235581B2 (en) 2007-06-26
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
JP4335142B2 (ja) 2009-09-30
CA2496756C (en) 2012-01-10
US20040116707A1 (en) 2004-06-17
TW200410935A (en) 2004-07-01
UY27991A1 (es) 2004-03-31
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
AU2003270213B8 (en) 2009-03-05
AU2003270213A1 (en) 2004-04-08
DE60333202D1 (de) 2010-08-12
HRP20050263A2 (en) 2006-12-31
GT200300204A (es) 2004-04-29
TWI286132B (en) 2007-09-01
HRP20050262A2 (en) 2006-06-30
CY1110745T1 (el) 2015-06-10
RU2005111968A (ru) 2006-11-10
NO20050652L (no) 2005-03-08
US7151111B2 (en) 2006-12-19
ZA200501311B (en) 2006-10-25
HRP20050261A2 (en) 2006-05-31
NZ538046A (en) 2007-08-31
US20040097578A1 (en) 2004-05-20
TW200408624A (en) 2004-06-01
UY27993A1 (es) 2004-03-31
AR041298A1 (es) 2005-05-11
PA8583001A1 (es) 2004-04-23
KR20050057450A (ko) 2005-06-16
ZA200501137B (en) 2006-12-27
PE20050078A1 (es) 2005-02-28
CA2498785A1 (en) 2004-04-01
KR20050057466A (ko) 2005-06-16
JO2604B1 (en) 2011-11-01
PT1542970E (pt) 2010-07-19
PL376018A1 (en) 2005-12-12
ZA200501557B (en) 2005-09-08
PL376021A1 (en) 2005-12-12
PE20050079A1 (es) 2005-03-01
ATE459601T1 (de) 2010-03-15
AU2003273901B2 (en) 2008-07-10
MY134480A (en) 2007-12-31
NZ538048A (en) 2007-05-31
AU2003267381A1 (en) 2004-04-08
DE60331559D1 (de) 2010-04-15
ES2344557T3 (es) 2010-08-31
GT200300206A (es) 2004-04-29
RU2323209C2 (ru) 2008-04-27

Similar Documents

Publication Publication Date Title
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
RS50918B (sr) Novi estri fluorenkarbonske kiseline, postupak za njihovo pripremanje, kao i njihova upotreba kao lekova
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
ATE348814T1 (de) Verfahren zur herstellung von chinolinderivaten
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20090837A1 (es) Nuevos compuestos quimicos
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
PE20040667A1 (es) Derivados de cinamida
DE60315664D1 (de) Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten
PE20040520A1 (es) Derivados de n-acilamino bencil eter
PE20040594A1 (es) Derivados de isoquinolina
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
HRP20100023T1 (hr) Postupak za pripremu karvedilola i njegovih enantiomera
DK1606276T3 (da) Fremstilling og anvendelse af 2-substituerede 5-oxo-3-pyrazolidincarboxylater
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
DE60310609D1 (de) Verfahren zur herstellung von 2-aminomethylpyridin-derivaten
BRPI0508996A (pt) processo para preparação de derivados de n-aril-piperazina
EA200500133A1 (ru) Производные пирролидина в качестве антагонистов окситоцина
NO20073213L (no) Fremgangsmate for fremstilling av tiofenglykosidderivater
WO2005040129A3 (en) Ccr3 receptor antagonists
ATE546432T1 (de) Verfahren zur herstellung von 2- aminomethylpyridin-derivate
ATE380183T1 (de) Verfahren zur herstellung von phenyltetrazolderivaten
SE0302281D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed